H Clifford Lane
Overview
Explore the profile of H Clifford Lane including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
212
Citations
25149
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chandrasekaran P, Berry I, Callier V, Anthony S, Hensley K, Kuhn J, et al.
J Infect Dis
. 2024 Dec;
PMID: 39718991
Background: The robustness and persistence of vaccine antigen-induced antibodies are often used as proxy indicators of vaccine efficacy, but immune responses to vaccine vectors are typically less well-defined. Our study...
2.
Valayer S, Alexandre M, Prague M, Beavogui A, Doumbia S, Kieh M, et al.
Emerg Microbes Infect
. 2024 Nov;
14(1).
PMID: 39559990
rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo are WHO-prequalified vaccination regimens against Ebola virus disease (EVD). Challenges associated with measuring long-term clinical protection warrant the evaluation of immune response kinetics after vaccination. Data...
3.
Davey Jr R, Collins G, Rouphael N, Poliquin G, McConnell R, Grubbs G, et al.
Lancet Microbe
. 2024 Oct;
5(11):100923.
PMID: 39374605
Background: rVSVΔG-ZEBOV-GP is the first approved vaccine with clinical efficacy against Ebola virus disease. Although a seroprotective threshold has not been defined for those at occupational risk of exposure, the...
4.
Gulick R, Pau A, Daar E, Evans L, Gandhi R, Tebas P, et al.
Ann Intern Med
. 2024 Sep;
177(11):1547-1557.
PMID: 39348691
Description: In March 2020, the White House Coronavirus Task Force determined that clinicians in the United States needed expert treatment guidelines to optimally manage patients with COVID-19, a potentially life-threatening...
5.
6.
7.
Singh K, Rubenstein K, Callier V, Shaw-Saliba K, Rupert A, Dewar R, et al.
J Infect Dis
. 2024 Apr;
230(3):624-634.
PMID: 38657001
Background: Although antivirals remain important for the treatment COVID-19, methods to assess treatment efficacy are lacking. Here, we investigated the impact of remdesivir on viral dynamics and their contribution to...
8.
Dodd L, Lane H, Muyembe-Tamfum J
NEJM Evid
. 2024 Feb;
3(3):EVIDe2300348.
PMID: 38411453
In 1970, the first case of mpox (formerly known as monkeypox) was documented in an infant in Equateur Province, Democratic Republic of Congo (DRC). Infections with clade I monkeypox virus...
9.
Alipanah-Lechner N, Hurst-Hopf J, Delucchi K, Swigart L, Willmore A, LaCombe B, et al.
Crit Care
. 2024 Feb;
28(1):56.
PMID: 38383504
Background: Despite evidence associating inflammatory biomarkers with worse outcomes in hospitalized adults with COVID-19, trials of immunomodulatory therapies have met with mixed results, likely due in part to biological heterogeneity...
10.
Scrimieri F, Bastian E, Smith M, Rehm C, Morse C, Kuruppu J, et al.
J Infect Dis
. 2024 Jan;
229(6):1786-1790.
PMID: 38226493
A subset of antiretroviral therapy-treated persons with human immunodeficiency virus (HIV), referred to as immunological nonresponders (INRs), fails to normalize CD4+ T-cell numbers. In a case-control study involving 26 INRs...